Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : gemcitabine
  • Active substance : ifosfamide
Filter
Topic
  • Economics and public health (1)
  • Plus ...
    • Organisation of care (1)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Cancers - miscellaneous (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Language
  • Français (1)
Active substance
  • acide folique (1)
  • alemtuzumab (1)
  • chlorure de sodium (1)
  • ciprofloxacine (1)
  • cisplatine (1)
  • cyclophosphamide (1)
  • gemcitabine (1)
  • ifosfamide (1)
  • oxaliplatine (1)
  • paclitaxel (1)
  • pentostatine (1)
  • rituximab (1)
  • trastuzumab (1)

Practice guidelines and other guides - 1 result

  • Patient selection criteria for at-home cancer chemotherapy

    Practice guidelines - Posted on 1/9/2003
    Download abstract
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
JqADuKwk0ZzhjwvY